Stem Cell Market Research Reports & Industry Analysis
Cells must meet very specific criteria in order to be termed stem cells. They must: produce copies themselves; proliferate at a rapid rate; and display certain proteins on their surface that indicate a capacity to differentiate into other tissues, such as bone and cartilage. A stem cell line is a group of cells that all descend from a single original stem cell. Symmetric division gives rise to two identical daughter cells both endowed with stem cell properties. Asymmetric division produces only one stem cell and a progenitor cell with limited self-renewal potential.
Stem Cell Industry Research & Market Reports
-
Amyotrophic Lateral Sclerosis Treatment Market Report by ALS Type (Sporadic ALS, Familial ALS), Drug Type (Marketed Drugs, Emerging Drugs), Diagnosis Type (Electromyogram, MRI, Blood and Urine Tests, Spinal Tap, Muscle Biopsy), Treatment (Medication, Stem Cell Therapy, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Region 2025-2033
... during 2025-2033. Amyotrophic Lateral Sclerosis (ALS) Treatment refers to a degenerative disease that affects the nerve cells in the spinal cord and brain, resulting in loss of muscle control. It primarily occurs due to gene ... Read More
-
Mesenchymal Stem Cells / Medicinal Signaling Cells (MSCs) - Advances & Applications, 2025
... cell types, such as osteoblasts, chondrocytes, myocytes, and adipocytes. Their unique ability to secrete factors that promote tissue repair and modulate their microenvironment with anti-inflammatory and anti-fibrotic effects makes them essential in regenerative medicine. Furthermore, ... Read More
-
CAR T-cell Therapy - Pipeline Insight, 2025
... stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage CAR T-cell Therapy ... Read More
-
Mesenchymal Stem Cells (MSC)
... 2030, growing at a CAGR of 12.2% over the analysis period 2024-2030. Bone Marrow, one of the segments analyzed in the report, is expected to record a 13.2% CAGR and reach US$3.4 Billion by the ... Read More
-
Amyloidosis Treatment
... CAGR of 6.8% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$3.7 Billion by the end of the analysis period. ... Read More
-
Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Global Market Report 2025
... This report focuses on cell and gene therapy contract development and manufacturing organization (cdmo) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over ... Read More
-
Cell Banking Outsourcing Global Market Report 2025
... market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond. Reasons to Purchase Gain a truly global perspective ... Read More
-
Primary Cells
... CAGR of 7.1% over the analysis period 2024-2030. Human Primary Cells, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$1.4 Billion by the end of the ... Read More
-
Cell Therapy
... CAGR of 14.1% over the analysis period 2024-2030. Allogenic Cell Therapy, one of the segments analyzed in the report, is expected to record a 12.8% CAGR and reach US$23.4 Billion by the end of the ... Read More
-
GMP Cell Banking Services
... 2030, growing at a CAGR of 15.2% over the analysis period 2024-2030. Mammalian Cell, one of the segments analyzed in the report, is expected to record a 16.1% CAGR and reach US$1.5 Billion by the ... Read More
-
Stem Cell Manufacturing
... at a CAGR of 7.8% over the analysis period 2024-2030. Culture Media, one of the segments analyzed in the report, is expected to record a 7.6% CAGR and reach US$9.2 Billion by the end of ... Read More
-
Allogeneic Stem Cells
... at a CAGR of 10.9% over the analysis period 2024-2030. Regenerative Therapy, one of the segments analyzed in the report, is expected to record a 11.8% CAGR and reach US$1.6 Billion by the end of ... Read More
-
Circulating Tumor Cell (CTC) Diagnostics
... Billion by 2030, growing at a CAGR of 11.1% over the analysis period 2024-2030. Detection & Enrichment, one of the segments analyzed in the report, is expected to record a 10.7% CAGR and reach US$15.4 ... Read More
-
Cell and Gene Therapy Market Dynamics by Disease Type: Development, Trends, and Forecasts, 4th Edition (2024-2030)
... Kalorama Information explores the transformative potential of cell and gene therapies in modern medicine. These therapies offer groundbreaking treatments by addressing genetic causes of diseases and modulating the immune system. The report highlights the surge ... Read More
-
Chimeric Antigen Receptor T-Cell Therapy (CAR-T) - Pipeline Insight, 2025
... drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography ... Read More
-
Biopreservation
... 8.0% over the analysis period 2024-2030. Biopreservation Media, one of the segments analyzed in the report, is expected to record a 8.7% CAGR and reach US$5.1 Billion by the end of the analysis period. Growth ... Read More
-
ADME-Toxicology Testing
... CAGR of 11.2% over the analysis period 2024-2030. Cell Culture, one of the segments analyzed in the report, is expected to record a 13.2% CAGR and reach US$9.6 Billion by the end of the analysis ... Read More
-
Amniotic Products
... CAGR of 8.1% over the analysis period 2024-2030. Amniotic Membranes, one of the segments analyzed in the report, is expected to record a 8.6% CAGR and reach US$1.2 Billion by the end of the analysis ... Read More
-
Cell Expansion
... CAGR of 14.8% over the analysis period 2024-2030. Cell Expansion Consumables, one of the segments analyzed in the report, is expected to record a 16.0% CAGR and reach US$42.4 Billion by the end of the ... Read More
-
Canine Stem Cell Therapy
... 2030, growing at a CAGR of 3.4% over the analysis period 2024-2030. Allogeneic Stem Cells, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$174.8 Million by ... Read More
-
CAR T-cell Therapy
... at a CAGR of 22.0% over the analysis period 2024-2030. DLBCL Indication, one of the segments analyzed in the report, is expected to record a 18.6% CAGR and reach US$5.1 Billion by the end of ... Read More
-
Stem Cells
... CAGR of 7.4% over the analysis period 2024-2030. Adult Stem Cells, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$17.8 Billion by the end of the ... Read More
-
Viral Vector Manufacturing
... at a CAGR of 18.3% over the analysis period 2024-2030. Retroviral Vectors, one of the segments analyzed in the report, is expected to record a 18.1% CAGR and reach US$954.6 Million by the end of ... Read More
-
Primary Immunodeficiency Therapeutics
... at a CAGR of 6.4% over the analysis period 2024-2030. Antibody Deficiency, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$8.5 Billion by the end of ... Read More
-
Cancer Stem Cells
... at a CAGR of 8.5% over the analysis period 2024-2030. Stem Cell-based Cancer Therapy, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$1.3 Billion by the ... Read More
Research Assistance
